UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 10, 2004
The Medicines Company
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31191 04-3324394
--------------------------------------- ------------------------- --------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
8 Campus Drive
Parsippany, New Jersey 07054
------------------------------------------------------------- ---------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 656-1616
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 12. Disclosure of Results of Operations and Financial Condition.
On February 10, 2004, The Medicines Company (the "Company") announced
its financial results for the quarter and full year ended December 31, 2003. The
full text of the press release issued in connection with the announcement is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE MEDICINES COMPANY
Date: February 10, 2004 By: /s/ Steven H. Koehler
---------------------
Steven H. Koehler
Vice President and Chief Financial Officer
Exhibit Index
Exhibit No. Description
----------- -----------
99.1 Press release dated February 10, 2004 entitled "The
Medicines Company Reports Fourth Quarter and Full Year
2003 Financial Results."